Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weider

This article was originally published in The Tan Sheet

Executive Summary

Schiff Move Free joint care sales of $31.7 mil. contribute to overall 1.3% sales increase to $91.2 mil. in fiscal first quarter (ended Aug. 31) despite "continued softening in industry and category trends," President & CEO Bruce Wood tells analysts Oct. 16. U.S. sales rose 2.2% to $65 mil.; consolidated net income rose 9% to $2 mil., although the increase reflects a one-time $3.5 mil. gain from a litigation settlement and $600,000 restructuring charge. New products and line extensions under Move Free, Weider, American Bodybuilding and Tiger's Milk brands achieved almost $6 mil. in sales. Weider plans to slow new product releases in FY 2001 and concentrate on top brands. Firm predicts continued flat revenues for the balance of the year and expects profitability from operating income

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel